Trial Profile
A Randomized Phase II Study of Pembrolizumab, an Anti-Programmed Cell Death (PD)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Oct 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Trastuzumab
- Indications Advanced breast cancer; Carcinoma; HER2 negative breast cancer; HER2 positive breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 18 Sep 2023 Planned End Date changed from 30 Sep 2023 to 30 Sep 2024.
- 18 Sep 2023 Planned primary completion date changed from 30 Sep 2023 to 30 Sep 2024.
- 08 Aug 2022 Planned End Date changed from 30 Sep 2022 to 30 Sep 2023.